Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) with a Sequential Switch to a 2nd IMT (MEDI4736) in Patients with Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

Study identifier:D4191C00011

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase IIa, Open-Label, Multi-Center, Multi-Cohort, Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) with a Sequential Switch to a 2nd IMT (MEDI4736) in Patients with Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV)

Medical condition

Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV)

Phase

Phase 2

Healthy volunteers

No

Study drug

Gefitinib, AZD9291, Selumetinib+Docetaxel, Tremelimumab

Sex

All

Actual Enrollment

32

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 25 Jul 2014
Primary Completion Date: 11 Jun 2016
Study Completion Date: 11 Jun 2016

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Aug 2019 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

Quintiles

Inclusion and exclusion criteria